- Home
- BUSE vs GYRE Comparison
BUSE vs GYRE Comparison
Compare BUSE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- GYRE
- Stock Information
- Founded
- BUSE 1868
- GYRE 2002
- Country
- BUSE United States
- GYRE United States
- Employees
- BUSE N/A
- GYRE N/A
- Industry
- BUSE Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- BUSE Finance
- GYRE Health Care
- Exchange
- BUSE Nasdaq
- GYRE Nasdaq
- Market Cap
- BUSE 1.5B
- GYRE 1.3B
- IPO Year
- BUSE N/A
- GYRE N/A
- Fundamental
- Price
- BUSE $24.39
- GYRE $11.14
- Analyst Decision
- BUSE Hold
- GYRE
- Analyst Count
- BUSE 3
- GYRE 0
- Target Price
- BUSE $30.00
- GYRE N/A
- AVG Volume (30 Days)
- BUSE 247.6K
- GYRE 144.6K
- Earning Date
- BUSE 01-21-2025
- GYRE 11-13-2024
- Dividend Yield
- BUSE 3.98%
- GYRE N/A
- EPS Growth
- BUSE N/A
- GYRE N/A
- EPS
- BUSE 1.95
- GYRE N/A
- Revenue
- BUSE $446,371,000.00
- GYRE $105,033,000.00
- Revenue This Year
- BUSE N/A
- GYRE $25.32
- Revenue Next Year
- BUSE $55.20
- GYRE $12.95
- P/E Ratio
- BUSE $12.38
- GYRE N/A
- Revenue Growth
- BUSE N/A
- GYRE N/A
- 52 Week Low
- BUSE $21.68
- GYRE $8.26
- 52 Week High
- BUSE $28.97
- GYRE $30.39
- Technical
- Relative Strength Index (RSI)
- BUSE 30.62
- GYRE 47.54
- Support Level
- BUSE $25.96
- GYRE $9.61
- Resistance Level
- BUSE $26.44
- GYRE $12.94
- Average True Range (ATR)
- BUSE 0.67
- GYRE 1.17
- MACD
- BUSE -0.36
- GYRE 0.13
- Stochastic Oscillator
- BUSE 12.10
- GYRE 47.06
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.